The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.

At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving ...

Although the SYMMETRY Phase IIb trial of the FGF21 analogue efruxifermin did not meet its primary endpoint at 36 weeks, ...

How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical ...

With technology/AI taking over administrative and repetitive tasks, human roles will shift towards more strategic, creative, ...

Brian Ongioni, chief product officer, uMotif, discusses how AI and machine learning can enhance patient-reported outcomes by ...

Cashin, MD, chief medical officer, Novotech, explores how CRO partnerships are shifting to deliver greater efficiency, ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

Brian Ongioni, chief product officer, uMotif, explains how early site feedback and patient involvement in software ...

Cashin, MD, chief medical officer, Novotech, emphasizes the importance of proactive communication, strategic alignment, and ...

Brian Ongioni, chief product officer, uMotif, explains how early patient feedback plays a crucial role in shaping digital ...

Cashin, MD, chief medical officer, Novotech, shares insights on how sponsors and CROs can cultivate a “one team” mindset by ...